4559 Zeria Pharmaceutical
- 2310
- -3-0.13%
Zeria Pharmaceutical News
Zeria Pharmaceutical: Notice of conclusion of a marketing and distribution agreement between Tillotts Pharma and Pioneer Pharma in the People's Republic of China
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2025[Under Japanese GAAP]
Zeria Pharmaceutical: Summary of Financial Results for the second quarter 2025
Zeria Pharmaceutical: Notice regarding changes in responsibilities of executive officers
Zeria Pharmaceutical: Announcement of the new release of “Heparise W Shine”
Zeria Pharmaceutical: Notice of obtaining approval for manufacture and sale of the drug ZG-801 (Virtasa) for treating hyperkalemia
Zeria Pharmaceutical: [Delay] The consolidated financial results for the first three months of the fiscal year ending on March 31, 2025 [based on Japanese accounting standards].
Zeria Pharmaceutical: Overview of Q1 2025 earnings report.
Zeria Pharmaceutical: Announcements of individual stocks: Development and sales contract for functional dyspepsia treatment using acotiamide hydrochloride hydrate in European, USA, and Canada regions.
Zeria Pharmaceutical: Announcements of individual stocks regarding the absorption merger (simple merger, abbreviated merger) of a wholly-owned subsidiary.
Zeria Pharmaceutical: Announcements of individual stocks regarding compliance with listing maintenance criteria.
Zeria Pharmaceutical: [Delayed] Consolidated Earnings for the Fiscal Year Ended 2024/3/31 [Japanese Accounting Standards]
Zeria Pharmaceutical: 2024 financial results overview
Zeria Pharmaceutical: Notice regarding executive personnel affairs
Zeria Pharmaceutical: Notice Concerning Organizational Changes and Executive Personnel
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2024[Japanese GAAP]
Zeria Pharmaceutical: Summary of Financial Results for the third quarter 2024
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2024[Japanese GAAP]
Zeria Pharmaceutical: Summary of Financial Results for the second quarter 2024
Zeria Pharmaceutical: Notice of new releases of “Prevaline Alpha Quick Ointment” and “Prevaline Alpha Quick Cream”
No Data